What to know
- ACIP's next meeting will be held on April 15–16, 2025.
- Get meeting information and read draft vote language below.
Summary of anticipated votes
Several votes are planned during the April 15–16, 2025 ACIP meeting.
The vote language shown below is considered draft. All vote language is subject to change and will continue to be updated in advance of the ACIP meeting.
Anticipated votes
Meningococcal Vaccines
Draft Vote: ACIP recommends GSK's MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit*
*1) healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and 2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia)
Draft VFC Vote: ACIP recommends the Meningococcal Vaccines VFC resolution be updated to include the recommendation for use of GSK's MenABCWY vaccine when both MenACWY and MenB are indicated at the same visit*
*1) healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and 2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia)
RSV-Adult Vaccines
Draft Vote: ACIP recommends adults 50–59 years of age who are at increased risk of severe RSV diseasea receive a single dose of RSV vaccine.b,c
- a. ob体育 will publish Clinical Considerations that describe chronic medical conditions and other risk factors for severe RSV disease for use in this risk-based recommendation.
- b. At this time, RSV vaccination is recommended as a single dose only. Persons who have already received RSV vaccination are NOT recommended to receive another dose.
- c. RSV vaccine can be administered with any product licensed in this age group. As of March 27, 2025, that includes GSK's Arexvy and Pfizer's Abrysvo. There is no preferential
recommendation for any licensed product over another.
Chikungunya Vaccines
Draft Vote 1: ACIP recommends the virus-like particle chikungunya vaccine for persons traveling to a country or territory where there is a chikungunya outbreak.
In addition, the virus-like particle chikungunya vaccine may be considered for persons traveling or taking up residence in a country or territory without an outbreak but with elevated risk for US travelers if planning travel for an extended period of time e.g., 6 months or more.
Draft Vote 2: ACIP recommends the virus-like particle chikungunya vaccine for laboratory workers with potential for exposure to chikungunya virus.
Draft Vote 3: ACIP recommends the live attenuated chikungunya vaccine for persons traveling to a country or territory where there is a chikungunya outbreak.
In addition, the live attenuated chikungunya vaccine may be considered for persons traveling or taking up residence in a country or territory without an outbreak but with elevated risk for US travelers if planning travel for an extended period of time e.g., 6 months or more.